TAT-Epsilon-V1-2 TFA is a cell-permeable PKCε peptide inhibitor. TAT-Epsilon-V1-2 TFA reduces chronic immune responses after heart transplantation. TAT-Epsilon-V1-2 TFA is applicable to research related to delayed graft function and acute kidney injury caused by renal ischemia-reperfusion injury [1] [2].
In Vitro, TAT-Epsilon-V1-2 TFA links the PKCε inhibitory peptide sequence (εV1‑2) to the TAT protein transduction domain, which facilitates the molecule's penetration through cell membranes.
References:
[1]. Marrocco V, et al. PKC and PKN in heart disease. Journal of molecular and cellular cardiology. 2019 Mar;128:212-226.
[2]. Sleeper S, et al. Myristoylated Protein Kinase C Epsilon Inhibitor Preserves Renal Function in a Mouse Model of Acute Bilateral Kidney Ischemia-Reperfusion Injury.
In Vitro, TAT-Epsilon-V1-2 TFA links the PKCε inhibitory peptide sequence (εV1‑2) to the TAT protein transduction domain, which facilitates the molecule's penetration through cell membranes.
References:
[1]. Marrocco V, et al. PKC and PKN in heart disease. Journal of molecular and cellular cardiology. 2019 Mar;128:212-226.
[2]. Sleeper S, et al. Myristoylated Protein Kinase C Epsilon Inhibitor Preserves Renal Function in a Mouse Model of Acute Bilateral Kidney Ischemia-Reperfusion Injury.